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Topical corticosteroids are the therapy of choice for nonaller- 
gic, noninfectious perennial rhinitis (NANIPER). However, 
the efficacy of steroid therapy in NANIPER is controversial, 
as is its mode of action. To our surprise, of 300 patients ini- 
tially diagnosed as having NANIPER, only 65 reached 
threshold nasal symptom scores. Patients were randomized 
into four different treatment regimens: placebo administered 
twice daily (BD) for 8 weeks, fluticasone propionate aqueous 
nasal spray (FPANS) (200 p~g) once daily (OD) and placebo 
OD for 8 weeks, FPANS (200 ixg) OD and placebo OD for 4 
weeks followed by FPANS (200 [xg) BD for 4 weeks, and 
FPANS (200 ~g) BD for 8 weeks. A small decrease in nasal 
symptoms was found, which only reached significance for 
sneezing in the FPANS 200 p~g BD group. A significant dose- 
dependent decrease in immunocompetent cells was found in 
nasal biopsy specimens obtained before, after 4 weeks, and 
after 8 weeks of treatment. We conclude that FPANS did not 
significantly reduce nasal symptoms in this group of selected 
NANIPER patients, even though a significant effect on cells 
in the nasal mucosa was seen. (J Allergy Clin Immunol 1997; 
100:739-47.) 
Key words: Nonallergic, noninfectious perennial rhinitis, topical 
steroids, fluticasone propionate, nasal biopsies, 
irnmunohistochemistry, nasal symptoms 
Topical corticosteriods became firmly established as 
the therapy of choice for allergic rhinitis in the last 
decades. Patients with this disorder do greatly benefit 
from this treatment, l, 2 The effects of local steroids in the 
nasal mucosa in allergic rhinitis have been well docu- 
mented? -5 The first studies showing the efficacy of 
topical steroids in nonallergic, noninfectious perennial 
rhinitis (NANIPER) were performed in the late 1970s 
and the early 1980s. 6-8 Recent studies that have used 
fluticasone propionate aqueous nasal spray (FPANS) for 
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Abbreviations u ed 
BD: Twice daily 
DRC: Daily record chart 
FPANS: Fluticasone propionate aqueous nasal 
spray 
mAb: Monoclonal antibody 
NANIPER: Nonallergic, noninfectious perennial rhi- 
nitis 
OD: Once daily 
PBS: Phosphate-buffered saline 
ssAP: Supersensitive immunoalkaline phospha- 
tase 
VAS: Visual analog scale 
the treatment of NANIPER have shown an efficacy 
comparable to that of topical steroids in the treatment of 
allergic rhinitis. 9 Philip and Togias, l° however, stated 
that although some clinical efficacy has been demon- 
strated in the treatment of NANIPER, these agents 
often failed to provide the same relief as they did in the 
treatment of allergic rhinitis. 
There are two theories concerning the etiology of 
NANIPER. 11 The first theory assumes an imbalance 
between adrenergic and cholinergic innervation of the 
nasal mucosa. 12 In this scenario, underactivity of the 
sympathetic nervous system leads to nasal obstruction, 
whereas overactivity of the parasympathetic nervous 
system leads to rhinorrhea, 3 Support for this theory was 
found by Wilde et al., 14 who showed an abnormal 
response to isometric exercise in patients with 
NANIPER, possibly caused by relative nasal sympa- 
thetic hyposensitivity. 
According to the second theory, NANIPER could be 
the result of an "overactive" nonadrenergic, noncholin- 
ergic system, resulting in neurogenic inflammation. 15,16 
Stimulation of sensory neurons results in sensory nasal 
changes, rhinorrhea, 17 nasal blockage, and sneezing. 
Sensory neural stimulation may produce these effects 
either through a central neural reflex associated with 
efferent parasympathetic neurotransmission r through 
antidromic release of neuropeptides from sensory neu- 
rons? 8 To support this hypothesis, Lacroix et al? 9 re- 
ported an increased concentration of neuropeptides in a 
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TABLE I. Selection criteria for NANIPER 
Inclusion criteria 
Age between 16 and 64 years 
Negative skin prick test response to house dust mite, tree 
pollen mix, grass pollen mix, bijvoet, Alternaria, Aspergil- 
lus, Cladosporiurn, Penicillurn, dog, cat, parakeet, rabbit, 
hamster, horse, guinea pig* 
Negative Phadiatop result 
Symptoms for more than 1 year 
Periods of nasal discharge, sneezing, and congestion for an 
average of at least 1 hour per day for at least 5 days dur- 
ing a period of 14 days 
Exclusion criteria 
Use of systemic or inhaled corticosteroids within the previ- 
ous month 
Use of inhaled sodium cromoglycate or nedocromil sodium 
within the previous month 
Use of astemizole within the previous month 
Inability of the patient o stop taking medication affecting 
nasal function 
A serious and/or unstable disease 
Nasal surgery within the previous 6 weeks 
Nasal polyps or a history of nasal polyps 
Significant anatomic abnormalities affecting nasal function 
Nasal or paranasal sinus infection (abnormal sinus roent- 
genogram) 
Pregnancy or lactation 
Abnormal laboratory results for 
Blood: Na, K, Ca, total protein, albumin, urea, creati- 
nine, bilirubin, alkaline phosphatase, aspartate amino- 
transferase, alanine aminotransferase, ~/glutamyl 
transpeptidase, hemoglobin, red blood cell count, 
plasma cell volume, mean corpuscular volume, plate- 
lets, total white blood cell count, neutrophils, lympho- 
cytes, monocytes, eosinophils, and basophils 
Urine: blood, protein, and glucose 
Abnormal findings at physical examination 
*Allergen extracts provided by ALK-Diephuis, Holland. 
group of patients with chronic rhinitis. A theoretical 
basis (animal experimental data) in accordance with the 
second theory for the efficacy of steroid therapy was 
found when steroids were reported to upregulate neutral  
endopeptidase, which degrades neuropeptides 2° and in- 
hibits neurogenic plasma extravasation. 21 
As a diagnosis made by exclusion, NANIPER proba- 
bly represents a heterogeneous group of pathophysio- 
logic conditions. To study this disorder in a second- 
echelon setting, we applied strict selection criteria. We 
excluded patients with systemic, medical, and anatomic 
disorders that could explain complaints of rhinorrhea, 
sneezing, and nasal obstruction. The remaining group 
was further homogenized on the basis of a daily record 
chart (DRC) on which patients had to reach a min imum 
symptom score. 
When modern  immunohistochemical  staining meth- 
ods are used, no data are available on the effect of local 
corticosteroid therapy on cellular infiltrates in the nasal 
mucosa of patients with NANIPER.  We studied the 
TABLE II. Daily record card 
Symptom Numeric score 
Nasal blockage (not 0 - Absent 
being able to 1 = Between 0-1 hr per half day 
breathe freely 2 - Between 1-2 hrs per half day 
through the nose) 3 = More than 2 hrs per half day 
Clear discharge 0 = Absent 
(runny nose) 1 = Between 0-1 hr per day 
2 = Between 1-2 hrs per day 
3 = More than 2 hrs per day 
Sneezing 0 = Absent 
1 Less than 5 periods per half day 
2 = Between 5 and 10 periods per 
half day 
3 = More than 10 periods per half day 
Coughing 0 = Absent 
1 = Less than 5 periods per half day 
2 - Between 5 and 10 periods per 
half day 
3 More than 10 periods per half day 
Mucus production 0 = Absent 
(yellow, green, or 1 = Present 
brown) 
Eye irritation 0 = Absent 
1 = Present 
All other medical complaints and medication taken during the day 
should be noted. 
effects of different reatment regimens for NANIPER on 
nasal complaints and cellular infiltrates. 
METHODS 
Patients were studied from 1988 to 1993 in the outpatient 
Ear, Nose, and Throat Departments of the Leyenburg Hospital 
in the Hague and the Dijkzigt University Hospital in Rotter- 
dam, The Netherlands. 
Patients were admitted to the study if they had a history of 
nasal complaints uch as nasal obstruction, sneezing, and 
rhinorrhea for a period of over 1 year, which could not be 
attributed to allergic rhinitis, nasal or paranasal sinus infection, 
anatomic disorders affecting nasal function (e.g., septal devia- 
tion, septal perforation, synechia, or bullous medial concha), 
pregnancy or lactation, systemic disorders, and/or the use of 
medication affecting nasal function (Table I). Patients with 
nasal polyps were excluded. Three hundred patients with the 
diagnosis of NANIPER were scored twice daily for the duration 
of their nasal complaints for a period of 2 weeks (run-in) by 
using a daily record chart (Table II). In affected patients, 
periods of nasal discharge, sneezing, and congestion had to 
persist for an average of at least 1 hour per day for at least 5 
days during a period of 14 days. The duration of complaints 
during the day was used as the prime criterion for further study. 
Sixty-five of the 300 patients were found to be eligible for our 
study and participated under conditions of informed consent 
(32 men and 33 women). They had a mean age of 34 years 
(range, 17 to 62 years). Twenty patients had never smoked, 16 
were former smokers (had not smoked for more than 1 year), 
and 29 were current smokers. The ethnic origin of the patients 
was as follows: 1 Oriental, 56 white, 2 black, and 6 Asian. 
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FIG. 1. Study design. 200, FPANS 200 ~g OD; 400, FPANS 200 ~g BD. 
Study  des ign 
A single-investigator, multicenter, double-blind, placebo- 
controlled study was done. All patients tarted with a run-in 
period of 2 weeks during which they received placebo doses of 
aqueous pray and recorded their nasal complaints. Eligible 
patients were randomized into one of four different reatment 
regimens: placebo administered twice daily (BD) for 8 weeks, 
FPANS (200 Ixg) once daily (OD) and placebo OD for 8 weeks, 
FPANS (200 Ixg) OD and placebo OD for 4 weeks followed by 
FPANS (200 ~g) BD for 4 weeks, and FPANS (200 Ixg) BD for 
8 weeks (Fig. 1). The treatment period was divided into two 
periods of 4 weeks. Terfenadine tablets (60 Ixg) were used as 
rescue medication. The study protocol was approved by the 
ethical review committees and conducted in accordance with 
the Declaration of Helsinki. 
Symptom scores 
For each of the symptoms of nasal blockage, sneezing, and 
rhinorrhea on waking and during the rest of the day, the scores 
were summarized separately by the percentage ofsymptom-free 
days as done by Scadding et al. 9 The scores for coughing, mucus 
production, eye irritation, and number of terfenadine tablets 
used were recorded. 
At every visit the subjects also rated the intensity of their 
nasal symptoms during the last 3 days on a visual analog scale 
(VAS) (0 to 10 cm; 0 represented absence of symptoms and 10 
represented severe intensity of symptoms). This was pragmati- 
cally considered to be the golden mean for moderating the 
extremes in nasal symptoms per patient by scoring intensity of 
symptoms over several days and by having a reasonably reliable 
recollection period of only 3 days. At each clinic visit the 
investigator scored the severity of the patient's symptoms of nasal 
blockage, sneezing, rhinorrhea, nd postnasal drip on a scale of 0 
to 3 (0 = no symptoms, 1 = mild symptoms, 2 = moderate 
symptoms, and 3 = severe symptoms). The nose was assessed by 
rhinoscopy. Turbinate swelling, crusting, bleeding, color of mu- 
cosa, and secretions were noted as normal or abnormal. 
Safety 
Safety was assessed by monitoring adverse events at each 
clinic visit. Biochemistry, hematology, and urinalysis results 
were determined at baseline and at the end of treatment. 
TABLE III. Monoclonal  ant ibodies used to study 
nasal mucosal  biopsy specimens of patients and 
control  subjects 
Antibody Specificity Titer Source 
OKT6 CD1 1:100 Dept. Immunology, Erasmus 
University, Rotterdam, 
The Netherlands 
Leu-4 CD3 1:25 BD, Dorset, U.K. 
Leu-3 CD4 1:50 BD, Dorset, U.K 
Leu-2 CD8 1:100 BD, Dorset, U.K. 
a-IgE IgE 1:250 Central aboratory of the 
Netherlands Red Cross 
Blood Transfusion Service 
(CLB), Amsterdam, The 
Netherlands 
IL-2r CD25 1:150 BD, Dorset, U.K. 
BMK13 MBP 1:200 Sanbio, Uden, The Nether- 
lands 
B7 Chymase 1:100 Chemicon, Temecula, Calif 
G3 Tryptase 1:250 Chemicon, Temecula, Calif 
Nasal  b iops ies 
Nasal biopsies were performed after the run-in period, after 
4 weeks of treatment, and after 8 weeks of treatment in each 
patient (Fig. 1). After randomization of the biopsy side, speci- 
mens of the nasal mucosa were taken from the lower edge of 
the inferior turbinate, about 2 cm posterior to the front edge, by 
using a Gerritsma forceps (Entermed, Woerden, The Nether- 
lands) with a cup diameter of 2.5 mm. 22 Local anesthesia was 
obtained by placing a cotton-wool carrier with 50 ixg of cocaine 
and one drop of epinephrine (1:1000) under the inferior 
turbinate without ouching the biopsy site. The specimens were 
embedded in Tissue-Tek II Optical Clear Tissue (O.C.T.; 
Sakura Finetek Europe BV, Zoeterwoude, The Netherlands) 
compound and frozen immediately. 
Nasal  brush cyto logy 
After the run-in period, a nasal brush sample was taken from 
the middle nasal meatus contralateral to the biopsy side by 
using the Gynobrush (Medeco, Eindhoven, The Netherlands). 
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FIG. 2. Mean increase in the percentage of symptom-free days recorded on DRC during days 1 to 70. 
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(FPANS vs placebo). 
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FIG. 3. Mean sum score and SD are shown for different treatment regimens in week preceding each visit. 
The brush was immediately placed in RPMI 52400 (Life 
Technologies, Breda, The Netherlands). Within 3 days, cytospin 
preparations were made and cells were stained with May- 
Grunwald-Giemsa tain and toluidine blue. 23 
Staining procedures 
Monoclonal antibodies (mAbs) directed against CD1, CD3, 
CD4, CD8, CD25, IgE, major basic protein, chymase, and 
tryptase (Table III) were used together with the supersensitive 
immunoalkaline phosphatase method. Sections of the nasal 
mucosa (6 Ixm) were cut on a cryostat (Jung Frigocut 2800E/ 
20/40), transferred to poly-l-lysine-coated microscope slides, 
dried, and fixed in acetone for 10 minutes at room temperature. 
They were then rinsed in phosphate-buffered saline (PBS) (pH 
7.6), placed in a half-automatic stainer (Sequenza, Shandon), 
incubated with 2% bovine serum albumin in PBS for 10 
minutes, and incubated with normal goat serum (Central 
laborato~ of the Netherlands Red Cross Blood Transfusion 
Service, Amsterdam, The Netherlands) for 10 minutes. The 
slides were subsequently incubated with the mAbs for 60 
minutes at room temperature. The sections were then rinsed 
again in PBS for 5 minutes and incubated for 30 minutes with 
a biotinylated goat anti-mouse (1:50) immunoglobulin anti- 
serum (Biogenics, Klinipath, Duiven, The Netherlands), rinsed 
successively in PBS, incubated with streptavidin AP (1:50) 
(Biogenics, Klinipath) for 30 minutes at room temperature, 
rinsed in PBS and Tris buffer (pH 8.5), and incubated for 30 
minutes with a new fuchsin substrate (Chroma, Kongen, Ger- 
many) at room temperature. Finally, sections were rinsed with 
distilled water, counterstained with Gills hematoxylin (Poly- 
sciences, Inc.) and mounted in glycerin-gelatin. Control staining 
was performed by substitution with PBS and incubation with an 
irrelevant mAb of the same subclass. The cytospin preparations 
were stained with toluidine blue (pH 0.5) for 5 minutes, and 
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FIG. 4. Mean VAS and SD are shown as recorded during each visit. 
counts were performed immediately. 24 Separate cytospin prep- 
arations were stained with May-Grunwald-Giemsa tain to 
study eosinophils. 
Light-microscopic evaluation 
Stained cells were counted in two sections of each biopsy 
specimen. The epithelium and lamina propria were evaluated 
separately. The total surface area of a section and its main parts 
(i.e., the epithelium and the lamina propria) were estimated 
with the use of the Kontron Image Analysis System Videoplan 
(Zeiss). The number of cells per square millimeter was calcu- 
lated for the epithelium and the lamina propria. 
Statistics 
The mean sum scores for blockage, sneezing, and congestion 
were calculated uring the week previous to visit 2, the week 
previous to visit 3, and the week previous to visit 4 because the 
effect of FPANS on nasal symptoms in our clinical experience 
reaches a steady state 1 to 2 weeks after the start of treatment. 
To moderate the fluctuations in DRC scores per patient, the 
mean sum score for 1 week was used. Statistical analysis of 
symptoms was carried out by testing differences from baseline 
among the four treatment groups (Kruskal-Wallis analysis of 
variance). Assessment by the investigator was analyzed with the 
chi-square test for trend. 
The biopsy data of the FPANS 200 txg OD group and the 
FPANS 200 Ixg OD followed by BD group were pooled for 
biopsy number 2 because these groups received the same 
treatment up to that moment (the first 4 treatment weeks). The 
Mann-Whitney U test was used to compare the differences in 
cell counts between different pairs of groups after significance 
had been established by using the Kruskal-Wallis analysis of 
variance among the four treatment groups. Ap value less than 
0.05 was considered a significant difference. 
We calculated the Spearman rank correlations between 
changes in cell numbers and the changes in the VAS scores per 
randomization group. 
RESULTS 
Symptom scores 
Fig. 2 shows the changes in the percentage of symp- 
tom-free days during the treatment compared with base- 
line. A small decrease in symptoms was found, which 
only reached significance for sneezing. The mean in- 
crease in the percentage of symptom-free days for 
sneezing in the FPANS 200 Ixg BD group was signif- 
icantly better than that in the placebo group when 
baseline and 8 weeks of treatment were compared 
(28% increase in percent points for the FPANS 200 
txg BD group vs 5% decrease in percent points for the 
placebo group). No significant difference between the 
four treatment groups was seen for coughing, mucus 
production, eye irritation, and number of terfenadine 
tablets used. No significant changes were seen for the 
mean sums of the scores (Fig. 3) (1 week before each 
visit) or the VAS score (Fig. 4) among the four 
treatment groups. There were no statistically signifi- 
cant differences among the four treatment regimens in 
the investigators' assessments of symptoms and rhi- 
noscopy at clinic visits. 
We found no correlation greater than 0.7 absolutely, 
which approximately coincides with testing at an c~ of 
0.01 between cell counts and nasal symptoms, given the 
size of the randomization groups. 
No major adverse vents occurred, and there were no 
relevant changes in the routine biochemical tests, hema- 
tologic tests, or urinalysis. 
Nasal brushes 
Five hundred cells were counted per cytospin. Tolui- 
dine blue-positive cells were found in just one cytospin 
(50 toluidine-blue positive cells per 500). Small n~z~- 
bers of eosinophils (<4 of 500) were sporadically (9-~f 
195 brushes) found in cytospins stained with May- 
Grunwald-Giemsa stain. 
Biopsy specimens 
The sections of the nasal mucosa had an average 
surface area of 1.6 mm 2 and usually showed a lining of 
ciliated columnar epithelium with or without goblet 
cells, partially stratified cuboidal epithelium, or both. 
The lamina propria usually consisted of a looser subep- 
ithelial cell-rich layer with most of the mucous glands 
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TABLE IV. Median cell numbers and 25th percentile and 75th percentile for the various treatment regimens at 
the end of the run-in period (after 4 weeks and 8 weeks of treatment) 
Run-in 4 weeks 8 weeks 
Median 25%-75% Median 25%-75% Median 25-75% 
Epithelium 
CD1 Placebo 55 22-134 23 0-122 50 27-126 
200 52 4-150 0 0-3 3 0-17 
200/400 83 35-110 0 0-16 0 0-3 
400 50 8-129 0 0-0 0 0-0 
CD3 Placebo 936 423-1143 488 250-848 347 215-656 
200 623 471-800 115 60-477 145 50-463 
200/400 652 331-1208 192 71-383 65 14-114 
400 403 257-789 151 38-348 210 10-317 
CD4 Placebo 386 190-544 255 104-514 187 86-331 
200 486 327-1192 63 14-162 78 10-167 
200/400 453 277-674 195 43-343 30 11-76 
400 336 184-716 20 6-93 ' 33 13-98 
CD8 Placebo 518 288-1018 224 129-629 92 37-241 
200 531 156-997 135 102-335 128 57-145 
200/400 448 127-663 141 73-228 24 9-80 
400 310 133-680 69 14-206 24 7-103 
CD25 Placebo 20 2-39 15 6-38 20 5-34 
200 0 0-20 4 0-36 4 0-13 
200/400 8,5 0-24 0 0-59 7 0-32 
400 0 0-18 0 0-20 4 0-27 
BMK 13 Placebo 0 0-7 0 0-5 0 0-10 
200 0 0-8 0 0-0 0 0-0 
200/400 0 0-0 0 0-0 0 0-0 
400 0 0-1 0 0-0 0 0-0 
Tryptase Placebo 0 0-20 0 0-0 0 0-2 
200 0 0-0 0 0-0 0 0-0 
200/400 0 0-12 0 0-0 0 0-0 
400 0 0-3 0 0-0 0 0-0 
Chymase Placebo 0 0-10 0 0-0 0 0-0 
200 3 0-22 0 0-0 0 0-0 
200/400 2 0-8 0 0-0 0 0-0 
400 0 0-5 0 0-0 0 0-0 
IgE Placebo 7,5 0-45 4 0-38 19 0-75 
200 0 0-6 0 0-0 0 0-14 
200/400 0 0-100 4 0-33 10 0-53 
400 0 0-80 0 0-16 0 0-0 
Lamina propria 
CD1 
CD3 
CD4 
CD8 
CD25 
Placebo 4 1-33 5 0-7 7 2.5-30 
200 3 0-9 0 0-1 1 0-4 
200/400 7 3-14 0 0-6 0 0-2 
400 4 1-18 0 0-0 0 0-0 
Placebo 586 446-1104 352 270-613 543 366-688 
200 446 274-804 397 147-537 386 237-814 
200/400 769 495-921 440 253-686 278 199-476 
400 405 226-741 347 271-576 355 125-1137 
Placebo 416 289-644 337 211-451 372 267-749 
200 309 206-536 187 139-518 393 161-748 
200/400 479 319-766 335 161-392 300 187-506 
400 325 162-586 152 73-517 284 204-529 
Placebo 376 200-655 279 188-329 186 111-399 
200 324 140-415 142 92-340 195 123-401 
200/400 292 174-603 296 216-479 155 108-229 
400 329 151-476 136 87-348 208 93-412 
Placebo 10 1-35 12 8-46 30 12-49 
200 0,5 0-5 3 1-3 17 3-38 
200/400 6 0-13 7 0-43 14 6-22 
400 2 0-75 15 1-33 10 5-34 
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TABLE IV. Cont'd 
Run-in 4weeks 8weeks 
Median 25%-75% Median 25%-75% Median 25-75% 
BMK13 Placebo 6 0-18 
200 2,5 0-8 
200/400 0 0-3 
400 1,5 0-4 
Tryptase Placebo 94 54-131 
200 86 43-117 
200/400 59 33-94 
400 66 34-79 
Chymase Placebo 86 47-125 
200 69 39-139 
200/400 61 51-105 
400 62 53-75 
IgE Placebo 36 5-98 
200 6 1-43 
200/400 31 17-99 
400 9 1-52 
3 1-19 8 1-25 
0 0-3 0 0-9 
0 0-13 0 0-2 
1 0-11 0 0-3 
39 28-75 50 19-78 
18 1-58 17 8-68 
31 16-39 24 14-37 
36 13-55 19 10-35 
73 46-109 53 25-106 
59 27-97 46 18-86 
53 35-63 49 27-66 
43 27-67 25 12-37 
24 5-79 32 8-121 
19 4-37 11 4-27 
21 3-59 26 6-69 
21 14-47 9 0-27 
TABLE V. Statistical evaluation after 4 weeks of 
t reatment  
400 vs 200 + 200 + 2001400 400 vs 
2001400 vs placebo placebo 
Epithelium 
CD 1 
CD 3 
CD 4 
CD 8 
CD 25 
BMK 13 
Tryptase 
Chyn~ase 
IgE 
Lamina propria 
CD 1 
CD 3 
CD 4 
CD 8 
CD 25 
BMK 13 
Tryptase 
Chymase 
IgE 
55 
5 
$5 
44 
445  
55 
+ +, 
The biopsy data from the FPANS 200 OD group and the data from the 
FPANS 200 OD for 4 weeks followed by FPANS 200 BD for 4 weeks 
group are pooled because these groups received the same treatment 
up to 4 weeks. 
Single arrow, p < 0.005; double arrow, p < 0.01; triple arrow, p < 0.001. 
and a deeper collagenous cell-poor layer. All sections 
were sufficiently deep to assess both layers. The sections 
were generally of good quality. Two biopsy specimens 
could not be evaluated because one had been defrosted 
and one had been n-iisplaced. The mAb supersensitive 
immunoalkaline phosphatase staining showed red cells 
against a blue counterstained background. T lympho- 
cytes, small round cells, were abundantly present in the 
TABLE Vl. Statistical eva luat ion after 8 weeks of 
t reatment  
200•400 
200 vs 400 vs vs 400 vs 400 vs 
placebo placebo placebo 200 200•400 
Epithelium 
CD1 $ ~, 
CD 3 ~, 
CD 4 
CD 8 
CD 25 
BMK 13 4 
Tryptase 
Chymase 
IgE 
Lamina propria 
CD 1 $ 
CD 3 
CD 4 
CD 8 
CD 25 
BMK 13 5 
Tryptase 
Chymase 
IgE 
54;  
5 
45 
;55  
~45 ; 
5 ;4  
455  
454  5 
4;  
$;  ; ;  
4 4 
Single arrow, p < 0.05; double arrow, p < 0.01; triple arrow, p < 0.001. 
epithelium and the lamina propria. Sometimes clusters 
o fT  cells were found in the epithelium Or the lamina 
propria (500 to 1000 cells). The occurrence Of these 
clusters did not differ between the groups. Langerhans 
cells, large dendritic cells, were found mostly in the 
epithelium. Only a few were present in the lamina 
propria. Mast cells were found mostly in the lamina 
propria and rarely in the epithelium. Eosinophils were 
rarely present in our material. Sometimes moderate 
infiltrates were found in the mucosa, but their occur- 
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rence did not differ among the groups in the first biopsy 
specimens. 
Nasal mucosa 
Median cell numbers and 25th percentile and 75th 
percentile are shown for CD1-, CD3-, CD4-, CD8-, 
CD25-, IgE-, major basic protein-, tryptase-, and chy- 
mase-positive c lls in the epithelium and lamina propria 
in Table IV. Table V (after 4 weeks of treatment) and 
Table VI (after 8 weeks of treatment) show the results 
after statistical evaluation for the different biopsy mo- 
ments and treatment regimens. No significant difference 
was found between the different groups before treat- 
ment (biopsy number 1). A marked effect on the number 
of Langerhans cells and T cells was seen. The effect of 
the double-steroid dose was more marked than that of 
the single dose. No additional effect of 4 consecutive 
weeks of steroid treatment was found after the first 4 
weeks of treatment in the epithelium. In the lamina 
propria, 4 extra weeks of treatment seemed to affect he 
mast cells and eosinophils if present. 
DISCUSSION 
Patients 
We were surprised that of the 300 selected patients, 
only 65 satisfied our condition for inclusion of nasal 
complaints for more than i hour a day. This underscores 
the importance of the use of nasal symptom scores to 
characterize patients. 
Symptoms 
The efficacy of 200 Ixg of FPANS daily or 400 p,g of 
FPANS daily in treating nasal symptoms in this second- 
echelon strictly selected group proved to be no greater 
than that of placebo. This contrasts with previous re- 
ports. However, of these early studies, only the study by 
Malta et al. 6 (n = 22) was placebo-controlled. Half of 
the patients in that study showed a nasal eosinophilia 
(patients with nonallergic rhinitis with eosinophilia syn- 
drome), which is known to be associated with a good 
response to steroidsY In our study no eosinophilia was 
shown. Furthermore, in the study by Malta et al., the 
reduction of baseline complaints by placebo was larger 
than the additional effect of steroid therapy. The efficacy 
of placebo has to be attributed partially to wetting the 
nose twice a day with the spray. 26 Scadding et al. 9 
reported on the clinical efficacy of topical steroids in a 
combined group of 371 patiens with allergic and nonal- 
lergic rhinitis. They concluded that topical steroids are 
efficacious in the treatment of allergic and nonallergic 
rhinitis. Unfortunately, no distinction was made between 
allergic and nonallergic patients as they were pooled in 
the separate treatment groups. The efficacy of treatment 
versus placebo was not separately tested for the nonal- 
lergic patients. The reported overall efficacy might per- 
haps be attributed to the known clinical efficacy in 
patients with allergic rhinltis. Furthermore, a significant 
reduction in nasal eosinophilia was seen in the nonaller- 
gic group, which was similar to that seen in the allergic 
group, again suggesting a substantial number of patients 
with nonallergic rhinitis with eosinophilia syndrome. 
The only significant decrease found in the percentage 
of symptom-free days was for sneezing, not the most 
important complaint of our patients. A significant effect 
was not found for any of the other assessment methods 
(i.e., VAS, DRC mean sum scores, assessment of nasal 
symptoms by investigator, and rhinoscopy). A small 
dose-dependent effect on symptoms, which was not 
significant, can be seen in the different graphs. Consid- 
ering the aforementioned results, we believe that the 
effect of FPANS on nasal symptoms in patients with 
NANIPER as we selected them is not clinically relevant. 
We believe that the patients with NANIPER seen by 
specialists these days do not have a cell-mediated dis- 
ease. 27 Currently, nasal steroids are often used as the 
first line of treatment before referring patients to a 
specialist. It is thus possible that the referred patients 
with NANIPER are mostly steroid nonresponders, 
which is in accordance with our clinical experience. 
Cells 
The concept Of NANIPER being caused by a neuro- 
genie inflammation, as presented by Wollf and others, 15 
is not supported by our findings. First, we found no 
differences in the numbers of inflammatory cells be- 
tween patients and control subjectsY Second, there is a 
lack of efficacy of nasal steroids in this group, whereas 
these steroids have been reported to be efifcacious in 
induced neurogenic inflammation. 21 
The absence of a correlation between the marked 
reduction in cell numbers of the immunocompetent cells 
and nasal complaints could be the result of two different 
phenomena. Either our groups are too small to measure 
an effect on nasal complaints, (although our group is 
larger than those of Malm et al. [n = 22] 6 and Pipkorn 
and Berge [n = 12] 8 who did find a significant reduction 
in nasal complaints) or the reduction in cell numbers by 
the steroid therapy in NANIPER is not clinically rele- 
vant. The reported reductions in cell numbers in re- 
sponse to the steroid treatment in allergic rhinitis are 
preceeded by an increase of immunocompetent cells in 
response to the allergic stimulus. In NANIPER, how- 
ever, no significant differences were found in immuno- 
competent cell numbers between patients and healthy 
control subjects. 27 Therefore it is more likely that the 
absence of a correlation in this study is relevant. 
The steroid effect in the nose seems to be cell-specific 
and not disease-specific. The Langerhans cells seem to 
be most sensitive to steroid therapy, as in allergic 
rhinitis. 4The T cells in the epithelium are also sensitive 
but to a lesser extent. Although our NANIPER data 
suggest only a moderate ffect on eosinophils and mast 
cells, which is not in line with the allergy data, this is 
probably due to the relative absence of these cells in 
NANIPER when compared with allergic rhinitis. If, even 
in small numbers, eosinophils and mast cells are present 
in patients with NANIPER, they are also reduced. There 
is an additional effect on cells if the dose of FPANS is 
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doub led  after 4 weeks  (FPANS OD fo l lowed by BD 
group) .  Th is  is in agreement  with data  f rom Godthe lp  et 
al. 4 on  pat ients  with perenn ia l  al lergic rhinit is.  The  
addi t iona l  effect of  the h igher  dosage o f  local stero id in 
NANIPER on the reduct ion  in cell numbers  has  not  
been  descr ibed before.  Whether  this has  impl icat ions in 
the  t reatment  of  s tero id - respons ive  pat ients  is quest ion-  
able. The  marked  effect of  a wett ing  agent  (i.e., p lacebo)  
in NANIPER as observed  by Ma lm et al. 6 and  Spector  26 
is not  seen in this study. Our  f indings as far as the  
p lacebo effect is concerned  are more  in l ine with those  of  
Scadd ing et al. 9 Th is  might  ref lect the  change  in the  
NANIPER popu la t ion  seen  by today's  special ist. 
To  conc lude,  the  "rh in i t is"  special ist  is increas ingly  
conf ronted  with a nonstero id - respons ive  NANIPER 
group.  Doub l ing  the t reatment  does  not  have  a signifi- 
cant  effect on  nasa l  symptoms.  A l though there  is a 
s ignif icant dose-dependent  s eroid effect on nasa l  immu-  
nocompetent  cells, this does  not  seem to be of  cl inical 
re levance.  
One  must  bear  in mind  that  this is a re fer red  and 
there fore  se lected group.  In a "virgin" (no prev ious  local 
steroid)  pat ient  with NANIPER,  local steroids are still 
the f irst- l ine t reatment .  Topica l  capsaic in therapy  might  
be a new therapy  for the  nonstero id -sens i t ive  group.  
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